-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
B/9GIg/Ft63pv+8LK2+WXN7/iWlWtJwYXHkloLtFJ2RXNmyBmJiXa6UK4lufwfZH
tHsgGEi0OTW0MxMSKLHzHA==
0001193125-04-004932.txt : 20040116
0001193125-04-004932.hdr.sgml : 20040116
20040115191234
ACCESSION NUMBER: 0001193125-04-004932
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 3
CONFORMED PERIOD OF REPORT: 20040114
ITEM INFORMATION: Other events
ITEM INFORMATION: Financial statements and exhibits
FILED AS OF DATE: 20040116
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNBIOTICS CORP
CENTRAL INDEX KEY: 0000719483
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 953737816
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-11303
FILM NUMBER: 04528325
BUSINESS ADDRESS:
STREET 1: 11011 VIA FRONTERA
CITY: SAN DIEGO
STATE: CA
ZIP: 92127
BUSINESS PHONE: 6194513771
8-K
1
d8k.htm
FORM 8-K
Form 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 14, 2004
SYNBIOTICS CORPORATION
(Exact name
of registrant as specified in its charter)
Commission
file number 0-11303
California |
|
95-3737816 |
(State or other jurisdiction of incorporation) |
|
(I.R.S. Employer Identification No.) |
11011 Via Frontera San Diego, California |
|
92127 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants
telephone number, including area code: (858) 451-3771
On January 14, 2004, we issued a press release announcing that we had received USDA approval for our Witness® HW in-clinic veterinary diagnostic for the detection of heartworm infection in dogs.
Item 7. |
|
Financial Statements, Pro Forma Financial Information and Exhibits |
|
a) |
Financial statements of businesses acquired |
|
b) |
Pro forma financial information |
|
99 |
Press release dated January 14, 2004, entitled Synbiotics Announces the Availability of Witness® HW. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
SYNBIOTICS CORPORATION |
|
|
|
Date: January 16, 2004 |
|
|
|
/s/ Keith A. Butler |
|
|
|
|
|
|
|
|
Keith A. Butler Vice President
Finance and Chief Financial Officer |
-1-
EXHIBIT INDEX
Exhibit No.
|
|
Exhibit
|
99 |
|
Press release dated January 14, 2004, entitled Synbiotics Announces the Availability of Witness® HW. |
EX-99
3
dex99.htm
PRESS RELEASE
Press Release
Exhibit 99
Paul R. Hays |
|
Keith A. Butler |
President & COO |
|
Vice President and CFO |
858-451-3771 x1401 |
|
858-451-3771 x1413 |
paulh@synbiotics.com |
|
keith@synbiotics.com |
SYNBIOTICS ANNOUNCES THE AVAILABILITY OF WITNESSñ HW
San Diego, California: January 14,
2004Synbiotics Corporation (OTCBB: SBIO) today announced the USDA approval of their Witness® HW in-clinic veterinary diagnostic for the detection of
heartworm infection in dogs. The heartworm test rejoins Synbiotics Witness® line of veterinary products that includes Witness® Relaxin, a pregnancy test for dogs and cats.
Synbiotics has been a leader in heartworm diagnostics since 1985. Their Witness®
HW kit rejoins DiroCHEK® , Synbiotics canine and feline heartworm microwell test, as one of the premier heartworm diagnostics available today.
Witness® HW, with its new American supply manufacturer, exceeds the quality expectations of our veterinary customers and meets the strict requirements of the USDA, according to Paul Hays, President and COO of
Synbiotics. We are pleased that our new relationship with a local company, with a proven record in the manufacture of high performance immunoassays, has so quickly enabled us to resume the supply of Witness® HW with the same Synbiotics antibodies as always. Our heartworm product will soon be followed by Witness® FeLV and Witness® CPV diagnostics for feline leukemia virus and canine parvovirus, respectively.
Synbiotics Corporation develops, manufactures and markets veterinary
diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego,
CA, and Lyon, France. For information on Synbiotics and its products, visit the Companys website at www.synbiotics.com.
With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that
could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by
others, the ability to assimilate acquired businesses, the continued effect on the business from our 2002 lack of liquidity, the seasonality of major portions of the Companys business and other risks set forth in Synbiotics Corporations
filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2002. These forward-looking statements represent Synbiotics Corporations judgment as of the date of the release. Synbiotics Corporation
disclaims, however, any intent or obligation to update these forward-looking statements.
***
GRAPHIC
4
g87096logo_1.jpg
GRAPHIC
begin 644 g87096logo_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``_`FD#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KQ#XO?&";X?WO
M@;P?X5T"Q\:?%#XG>(KK0O!/A"_\3P^%+"2ST+2KKQ%XR\6^(=8@TGQ/K6E>
M#O".AV/E:GK.D>#_`!*W_"4:YX-\*/:6]YXKL;B+VN5@BY)(],9Y/;IR>_RC
M)/H<&OD/]GV%?BQXL\3?M5:QH,NGVOC[1['P3\#?[6.DW.K1?L_Z)J5_K&C^
M-0EA>ZU'H$WQY\0ZF_Q&_L^UU2SU2[^%]A\"=,^(OA?PE\2O"/BCPQHI&%U5
MG+:$4Z:NU>?1>ZT]&KRU3:T6KTB4DI*&J.&YU7P!\2O"T^C_
M`!&^$GCJRMV\._$WX8>)_"GQ`\'W>H^&_$.GWLOY[_M>^(S^U'^UI\)?V)-"
MUO1K?P3X8U=/&?QDTQ;75;W6_%;6OA.2_P#&?AJ>`^3H=GX#^'GPJ^(/@X^*
M-8EL]4U?1?CM^T]^QCXK\+:SX6U'PEJT.N_4/[:,]I\"O!%_^VAX>TX2^,/V
M"/B/7?%7AK3-0N-&N?C=\(;?3-1N->^"!M['2?$,GB+Q7<:O=VOBKX#:/%
MI,VL3_&?3O#W@C2M7T#PS\3/B"VJ],Z=/V5&'(HXBNHN#4ZJ5ZEHPI5(3G./
MOR7NR3BES7EIJL(3DW*2E*4(/E;GRN^U^3EC%::;O5[GYU:3^T]^VE\3OC_%
MI6F?%W6/AIX0\3_%'2O"6AQ6OPD^$^K_``&^&UUJ7P3U7XLQ>!/'/Q0\4^);
M+XH>*/'O@]O#C^'_`(G_``XTKP+8ZGXH\5R7VA>%?B;\'--\6P>)/A/^TW[/
M7Q(U#XQ_`/X(?%W5]'7P[JOQ4^$7PW^(^I^'TEGN$T&_\<>#M&\37FBK/=6]
MIO-))JR25C6G!Q>D5S.RM)VA%II*UD[=6K[/HHHKG-0HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`_-+_@HS_P`%+OAM_P`$[_#W@"Z\5>%-1^(7C'XES>)V\+^#-&\1
M^'_#]P=*\&:?:7_B/7M7N-3>\U2UTF!M1TS2[.\TWP[JUM-KNIZ?IE_<:6;Z
MWN&^1?V+_P#@N1X+_;+^.*?`71?@M?\`@3Q1JW@WQ[X@\):I??$71?$.F>)=
M?\"V-AJTWA:"&U\/:9?QO?Z7-JNH17FFVNNWJ6V@ZB&T00Q7.HV?Y[_\'1G[
M(?Q/\8>&O@W^V+X)L-:\4^!OA7I.K^`/C9HNB6][=:GX$\,&;4O%?A;XL1I#
M'):VWA;2;UO$6A>-+Z[EBAT_4-8\#W5S:R:"?$NH:79_X((>'?\`@F+\9K3P
MA9Z'^S!\*_AW^V]^S1X7\,WL/Q#T^;6I/$'Q:\/Z-;+H%O\`&[P]JU_K'VK4
MO$\LE_!;_%+3[JWN9O#FL^+-,FN18:?XWMM"T_[^&49#2X*6
(O@+\8OV7OCO\`#OX'^&K#Q99V
MWPJU?PMXW_8"U[X76OP*\2:3XD_;R^&_P^\+_$CQ5^UWJ6M^-[#Q[KG_``3]
M^(6NZ5H&M>&VU#]LWP]X(2Z^%?@'^CSPK;_9XM=']D>*='\[Q3K]QL\5>(O^
M$CEU#SKUG_M?0I/^$I\5?V/X6U'_`%^@>'?-T/\`L6R*VG_"+:#C[$O4T4`?
MS$^(_P!@[]LB\^-_QE\Z1\:+3Q[^U1\&?V=-*\&?M)7_[<5]I/PQ\%
M?%G5M8L/@CJ7A+X/7MQ87O>_$7]E3]JWQ):?M":EX>_9-\L^*#9_M)>*+/\`
M9;U?XX^(CXT^%]KI]Q;ZGXHN_#^KR?T`?VJ_&/@.X^!_BO\`
M98B_;$TC]H3PC\4OA1^T-\>_V5O`7[.?P1\7^"OV8/$][I<$G[/OAGPK^UI^
MW9H?B2\\9_$/1KWQ!!J/Q=T?XF2^%/`VIV6G^-=&^%-SXG;3K+1OF#]IG]GO
M]I_]HKQS\8(M)_8'^)GP6T#X.ZK9Z/\`LOZM\.=3_8*TF#Q;X4UC]M/]G;X_
M_M/_`!J\,>)Y/VGM5U23]I'XSZ5\(8_'W[.7PO\`C9\$?!O[/FB?$_PG;^(?
MVL/$WQ!G^(4GA[X=_P!&]%`'XH?!;]F+_@HKX9_9!UWX6_#GXK^`O@1=>--<
M^/7B./P_\;?AY9:Y^U?8:_\`'W]KGXA?&;Q]\3O&O[1/[.GQPUK]FSP-\6/%
M'PY^(OBF[M/#GP=_9S\:_#?X>?&/4]-\1^%-4N?`FF6_PUT[Y9\*?L-_M-_#
M7]B70?V5/#/[(6F^"/&;_';]L.Z\`>+?V>O&G[,7_"M_AW\*=:_;O^+G[0OP
M(^$'QTN/C(;+XJV7[&7CBS\0>`O&.M:+^S%-J?[1%AX3\.:1X!
M/&7[7GC'XN_\%2_V7/V\_@G\4_@IXBU7XH)J.@^,/!G_``SGJ7Q!^*>B?M$P
M?`"XB^(WQ`U7P7X'^)GBC3;[7/B)>?LQ^QAH_P`>-#_9X\+V/[2%WXFN?B;)
MXO\`C)JEM:>.=6\$Z_\`$+PW\*-=^-7Q#UO]GSP-\3-?^&]QJ'@37_BC\/O@
M!J/PR\#?$W7?"NO>+]&UGQYX>\0ZE:>//'Z77_":Z]]2T4`?$O\`P4*_9=^,
M'[8W[+OC'X#?`K]K/XD?L2_$;Q-K?@W4],_:$^$\'B:?QOX8LO#/B?3M>U72
M--7PA\2/A/KRV_BFPL9M!U%[3QMIR"QO9UNK?4;9I;&?ZL^'_A[6/"7@/P3X
M4\0^*+WQOK_AGPCX;\/:YXTU*"2VU'Q?K&BZ-9:;J?BB_MYK[4Y;>]U^]MI]
M6NH)=2U"2*>[DC>^NV4SR==10!\@?\%"?A;X[^./[`O[_LE_&S_`()!:8_@;3/&
M,$FN3Z[<>.OB?K>AZKK%U/XC^"7QTT+_`(1[2?AW^X%%`'XE?LA?"K]O?0OC
M5X[\2_M3Z'^T;K_P:UGX9:%!\'_!MO\`M3>#]4USX??%$WGP5D_:.U+XAVGA
MCXF>%EU71_C'\2-'NOB'^S+I*^.OB];_``-^$?A+XX^!(-5^#6B_&_PS^SG%
M]M_\%$OA7\1_C/\`LF>-_`7PGT+6O$GC:;QW^S[XKMM*\)ZIX&T?Q^V@?#?]
MHKX4?$CQQ?\`PIOOBIJ.E_"5?C-HW@?PGXCUGX,6OQ@O!\'M1^*NG^#].^+-
MM??#NZ\2V-S]M44`?SJ?#']DO]KOX,?'_B/6?&'[<'B+5?BOX4U"?X4Z?H/AJ\LXOB'X:MOZ`J*`/YT/$_[!'[
M6UU\=_VJ?BK\-OV=?VR](^-'
MP0^$OP[LOC?;^#O!'PZ\/_`GP#X)\`W^C:7_`,+!\#>%_&?B33?$_B"_\=:=
M\2OB?\1O%^K_`$WX,_98_:$\6:__`,$O?C=\:O">O^)_C5^SU^U_^UEXH\9>
M)_'_`(P^'NK?$KX/?L??%7X$_P#!0?PC\#?!/CF\\'^()?`/BKXE:-H_Q(_9
M%^%_QIU'X477Q`N_%?Q`\-_\)/>^-?B)X6\+W/Q%/[*44`?C3^TE\!OVUM3\
M0?#'Q]IESX@^*'[6NA_#'XK?#3X6?M(_LS6O@']G;]F_X)ZSXY\8>!O%ME<_
MM"?LZ?'S]HSXH_$_QC\'=;U7X?\`PYN?BM8_"OXC_%[7OB!I?@%-.MOA9X3U
MG3_!_B*W^OO"G[/:_&:']IS4?VK?A]:Z_I7QM\?Z_P##O3/A?XNOM'U_0[?]
MF/X8:ROA?P!X7OK7PUK.JZ'?^$/C7?:'XA^/'B;PSJMY<:CK>B_%^W^'OQ5T
M:T'AZ?P!X<^V**`/YG?#/["?[:WA;X<_\$]_AMX<^'?B'PUKB_L/_P#!(_\`
M9]_::\5OJ/[/WBSPO\"-?_8(^+*_%WQJFG>)-0^,.E>-O"'BRSE\1^+;"WUW
AX*_##]IC3/C=K&E>!_#MCXJ_9>/A'3_CS??TQ444`?_9
`
end
-----END PRIVACY-ENHANCED MESSAGE-----